Our top pick for
Crane Co is a specialty industrial machinery business based in the US. Crane shares (CR) are listed on the NYSE and all prices are listed in US Dollars. Crane employs 11,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$93.18|
|52-week range||$48.10 - $104.57|
|50-day moving average||$95.08|
|200-day moving average||$94.88|
|Wall St. target price||$118.25|
|Dividend yield||$1.72 (1.85%)|
|Earnings per share (TTM)||$5.96|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-2.73%|
|1 month (2021-09-17)||1.47%|
|3 months (2021-07-16)||3.02%|
|6 months (2021-04-16)||-1.34%|
|1 year (2020-10-16)||71.13%|
|2 years (2019-10-16)||14.44%|
|3 years (2018-10-16)||2.68%|
|5 years (2016-10-14)||53.31%|
Valuing Crane stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Crane's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Crane's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Crane shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Crane's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6704. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Crane's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Crane's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $573.7 million.
The EBITDA is a measure of a Crane's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.1 billion|
|Operating margin TTM||14.3%|
|Gross profit TTM||$1 billion|
|Return on assets TTM||6.17%|
|Return on equity TTM||20.57%|
|Market capitalisation||$5.5 billion|
TTM: trailing 12 months
There are currently 429,280 Crane shares held short by investors – that's known as Crane's "short interest". This figure is 33.4% down from 644,669 last month.
There are a few different ways that this level of interest in shorting Crane shares can be evaluated.
Crane's "short interest ratio" (SIR) is the quantity of Crane shares currently shorted divided by the average quantity of Crane shares traded daily (recently around 254011.83431953). Crane's SIR currently stands at 1.69. In other words for every 100,000 Crane shares traded daily on the market, roughly 1690 shares are currently held short.
However Crane's short interest can also be evaluated against the total number of Crane shares, or, against the total number of tradable Crane shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Crane's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Crane shares in existence, roughly 10 shares are currently held short) or 0.0087% of the tradable shares (for every 100,000 tradable Crane shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Crane.
Find out more about how you can short Crane stock.
Dividend payout ratio: 31.05% of net profits
Recently Crane has paid out, on average, around 31.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.85% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Crane shareholders could enjoy a 1.85% return on their shares, in the form of dividend payments. In Crane's case, that would currently equate to about $1.72 per share.
While Crane's payout ratio might seem fairly standard, it's worth remembering that Crane may be investing much of the rest of its net profits in future growth.
Crane's most recent dividend payout was on 7 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 August 2021 (the "ex-dividend date").
Crane's shares were split on a 3:2 basis on 14 September 1998. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Crane shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Crane shares which in turn could have impacted Crane's share price.
Over the last 12 months, Crane's shares have ranged in value from as little as $48.1003 up to $104.5699. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Crane's is 1.6794. This would suggest that Crane's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Crane Co. manufactures and sells engineered industrial products in the United States, Canada, the United Kingdom, Continental Europe, and internationally. The company's Fluid Handling segment offers on/off valves and related products for the chemical, oil and gas, power, and general industrial end markets; valves and related products for the non-residential construction, general industrial, and municipal markets; fluid control instrumentation and sampling solutions; and pumps and related products for water and wastewater applications in industrial, municipal, commercial, and military markets. This segment sells its products under the Crane, Saunders, Jenkins, Pacific, Xomox, Krombach, DEPA, ELRO, REVO, Flowseal, Centerline, Resistoflex, Duochek, Barksdale, Westlock, WTA, HOKE, DOPAK, Stockham, Wask, Viking Johnson, IAT, Hattersley, NABIC, Sperryn, Wade, Deming, Weinman, Burks, and Barnes brands. Its Payment & Merchandising Technologies segment provides technology payment acceptance and dispensing products to original equipment manufacturers and for vertical markets; currency handling and processing systems, cash and cashless payment and merchandising solutions, equipment service solutions, and connected managed service solutions. The company's Aerospace & Electronics segment offers original equipment and aftermarket parts under the Hydro-Aire, ELDEC, Lear Romec, P. L.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.